On March 9, 2022 AIM ImmunoTech Inc. (NYSE: American AIM) ("AIM" or the "Company"), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, reported that oncology experts from Roswell Park Comprehensive Cancer Center will present findings from two ongoing clinical studies involving an AIM ImmunoTech Inc (Press release, AIM ImmunoTech, MAR 9, 2022, View Source [SID1234609787]). drug candidate, Ampligen (also known as rintatolimod) at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2022, being held April 8-13, 2022, in New Orleans, Louisiana.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Research led by Roswell Park medical oncologists Shipra Gandhi, MD, and Sarbajit Mukherjee, MD, MS, in collaboration with senior investigator Pawel Kalinski, MD, PhD, Chair of Immunology at Roswell Park, has been accepted for presentation as late-breaking poster abstracts at the meeting.
Details of the abstract and late-breaking poster presentations are as follows:
Title: Initial results of a phase II study evaluating a chemokine-modulatory (CKM) regimen in patients with colorectal cancer metastatic to the liver
Presenter: Sarbajit Mukherjee, MD, MS
Abstract Number: 22-LB-7312
Session: Phase II Clinical Trials 1, presentation CT105
Presentation Type: Late-breaking poster presentation
Session Date and Time: Monday, April 11, 2022, from 9 a.m. 12:30 p.m. CDT
Location: Poster 2, Section 33
Title: Systemic Rintatolimod and Interferon-α2b selectively reprogram local tumor microenvironment in patients with metastatic triple negative breast cancer for enhanced influx of cytotoxic T-lymphocytes but not regulatory T-cells
Presenter: Shipra Gandhi, MD
Abstract Number: 22-LB-7620
Session: Phase I Clinical Trials 1, presentation CT145
Presentation Type: Late-breaking poster presentation
Session Date and Time: Monday, April 11, 2022, from 1:30 to 5 p.m. CDT
Location: Poster 12, Section 35
The late-breaking and clinical trials abstract titles and authors are now available on the AACR (Free AACR Whitepaper) Online itinerary planner. The late-breaking and clinical trials abstract text is under embargo until April 8, 2022 at 1:00 p.m. ET.